Single-Cell Discovery Grant in Oncology and Immunology

Aug 30 2021

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunology

Open single-cell discovery grant for oncology and immunology up to 100K Euro aimed at addressing unmet clinical needs.

Immunological diseases and Cancer are complex disorders and pose an enormous clinical burden due to diagnosis, stratification, and treatment challenges. Single-cell technologies are powerful in analysing the cellular landscape within complex diseases and are increasingly popular as a tool in identifying rare cells underlying the etiology of disease onset and progression in these areas. We are opening a single-cell discovery grant for oncology and immunology.

Scailyte is a recognized leader in combining single-cell analysis with artificial intelligence (AI) based data analytics. Our best-in-class algorithm associates patterns in single-cell data with disease status and further integrates multiple clinical parameters for a sensitive and impactful discovery.

We offer a co-finance partnership sharing 50% of costs (up to 100K Euro) for single-cell data acquisition including scRNA sequencing and CyTOF analysis, and subsequent artificial intelligence (AI)-based high-end bioinformatics services for translational oncology and immunology projects. The expected outcome of these grants should be addressing unmet medical needs and targets the discovery of clinically relevant biosignatures from single-cell data for diagnostic and prognostic pharmaceutical use. A maximum of three projects will be selected for this award through a formal selection process and notified within one month of the deadline.

Application:

Link to the brief application form: Click Here

Deadline: 30th September 2021

Recent News

PAPER: Mapping single-cell data - Nature Biotech

Large single-cell atlases are now routinely generated to serve as references for the analysis of sma

Scailyte Closes Financing Round and Onboards Top Biotech Leaders

Scailyte has successfully finished the first closing of their series A. Two new investors joined the

Scailyte Quarterly Update December 2021

December 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

VACANCY: Regulatory Affairs / Quality Management Specialist

We are currently developing a first-in-class in vitro diagnostic tool for Endometriosis aiming at cu

Why single-cell technologies are vital for Endometriosis research webinar

Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of th